DDInter604 DDInter107
Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy.[L33199,L33174] Aside from its contraceptive effects, drospirenone is used with estrogens to control acne and premenstrual dysphoric disorder (PMDD). Drospirenone has been the subject of widespread safety concern due to the possibility of an increased risk of venous thromboembolism associated with its use.[A182543,A182552] In 2012, however, a safety statement by the FDA concluded that the increase in the risk of thromboembolism resulting from the use of drospirenone remains unclear, as studies regarding this risk are conflicting. Some studies have demonstrated a significantly increased risk and some demonstrating no risk of thrombo
Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors . In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or . Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines . Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males . Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis . Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death . In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment . In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo . Apalutamide displayed good tolerability and safety profile in clinical studies. Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer .
Drospirenone {u} (Compound) resembles {v} (Compound) Eplerenone
Eplerenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apalutamide
Drospirenone {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Drospirenone {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Drospirenone {u} (Compound) resembles {v} (Compound) Eplerenone
Eplerenone {u} may lead to a major life threatening interaction when taken with {v} Fluconazole
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Drospirenone {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} (Compound) resembles {v} (Compound) Eplerenone
Eplerenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apalutamide
Drospirenone {u} (Compound) resembles {v} (Compound) Norethisterone
Norethisterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Drospirenone {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Eplerenone
Eplerenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apalutamide
Drospirenone {u} (Compound) resembles {v} (Compound) Flurandrenolide
Flurandrenolide {u} (Compound) resembles {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Drospirenone {u} (Compound) resembles {v} (Compound) Hydrocortisone
Hydrocortisone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eplerenone
Eplerenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Apalutamide
Drospirenone {u} (Compound) resembles {v} (Compound) Eplerenone
Eplerenone {u} (Compound) resembles {v} (Compound) Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apalutamide
Drospirenone (Compound) resembles Eplerenone (Compound) and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Drospirenone (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Drospirenone (Compound) resembles Progesterone (Compound) and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Drospirenone (Compound) resembles Eplerenone (Compound) and Eplerenone may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Drospirenone (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate (Compound) resembles Eplerenone (Compound) and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Drospirenone (Compound) resembles Norethisterone (Compound) and Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Drospirenone (Compound) resembles Progesterone (Compound) and Progesterone (Compound) resembles Eplerenone (Compound) and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Drospirenone (Compound) resembles Flurandrenolide (Compound) and Flurandrenolide (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Drospirenone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Eplerenone and Eplerenone may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Drospirenone (Compound) resembles Eplerenone (Compound) and Eplerenone (Compound) resembles Medroxyprogesterone acetate (Compound) and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide